0000000000362261

AUTHOR

Giuseppa L. Sanfilippo

showing 2 related works from this author

Recombinant GII.P16 genotype challenges RT-PCR-based typing in region A of norovirus genome

2021

Abstract Objectives In latest years GII.4[P16] and GII.2[P16] noroviruses have become predominant in some temporal/geographical settings. In parallel with the emergence of the GII.P16 polymerase type, norovirus surveillance activity in Italy experienced increasing difficulties in generating sequence data on the RNA polymerase genomic region A, using the widely adopted JV12A/JV13B primer set. Two sets of modified primers (Deg1 and Deg2) were tested in order to improve amplification and typing of the polymerase gene. Methods Amplification and typing performance of region A primers was assessed in RT-PCR on 452 GII norovirus positive samples obtained from 2194 stool samples collected in 2016–2…

0301 basic medicineMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaGenotype030106 microbiologymedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundfluids and secretions0302 clinical medicineRNA polymeraseGenotypemedicineHumans030212 general & internal medicineTypingChildPolymerase GenePhylogenyPolymeraseCaliciviridae InfectionsbiologyReverse Transcriptase Polymerase Chain ReactionNorovirusvirus diseasesVirologyInfectious DiseasesReal-time polymerase chain reactionItalychemistryDegenerate primers GII.P16 Norovirus PolymeraseTypingNorovirusbiology.proteinPrimer (molecular biology)Journal of Infection
researchProduct

Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization

2022

Abstract Aims Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has had a serious worldwide impact on human health. On December 2020, an immunization campaign with a COVID-19 mRNA vaccine (Comirnaty-BNT162b2 Pfizer-BioNTech) was started in Italy, first targeting healthcare workers (HCWs). This study aims to investigate the antibodies that are response against SARS-CoV-2 vaccine. Methods and Results The kinetics and the persistence of both anti-S1/S2 IgGs and neutralizing antibodies (Nt-Abs) were investigated in 76 HCWs through a 4-month follow-up with multiple testing points starting at the first dose. Temporal analysis of SARS-CoV-2 Abs titre kinetics showed three diff…

Settore MED/07 - Microbiologia E Microbiologia ClinicaVaccines SyntheticCOVID-19 VaccinesSARS-CoV-2VaccinationCOVID-19General Medicineneutralizing antibodies.Settore MED/42 - Igiene Generale E ApplicataAntibodies ViralAntibodies NeutralizingApplied Microbiology and BiotechnologyKineticsItalyhealthcare workerImmunoglobulin GSpike Glycoprotein CoronavirusHumansmRNA Vaccineskinetics of antibodieBNT162 VaccineBiotechnologyJournal of Applied Microbiology
researchProduct